STOCK GOODIES PLAYS OF THE WEEK

[BioSpecialist]

AQSZF (MC $11 M) 2 Marketed Drugs + 3 Drugs nearing Approval

This completely undiscovered low float is definitely one of the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Aequus has begun to Market 2 Drugs called Vistitan (Glaucoma) and Tacrolimus IR (Transplant) in first half 2016 in Canada and they got the Canadian rights for the Epilepsy drugs Trokendi XR and Oxtellar XR from Supernus Pharma (SUPN) earlier this year , NDS submission for Approval is expected in early 2017 .Peak sales for these 4 drugs is between $40-45 Million according to Management which is HUGE for this microcap stock with a ridiculous market cap of $10 Million .Management alone holding over 16 Million shares Ceo just bought 840k shares at 0.30 a few days ago .GLTA


Aequus Pharma (AQS.V) (AQSZF)

Market-Cap: $11 M
Price: 0.22

Shares out: 54 Million


Presentation August 2016
http://www.aequuspharma.ca/Investors/Aequus%20Pharmaceuticals%20August%202016.pdf


Marketed Products :

Tacrolimus IR

Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)


Vistitan

•Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.


Topiramate XR (Epilepsy and Migraine) NDS submission to Health Canada in 1Q 2017 <<< Licensed from Supernus Pharma (SUPN)


Oxcarbazepine XR (Epilepsy) NDS submission to Health Canada in 1Q 2017 <<< Licensed from Supernus Pharma (SUPN)


NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License(If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)


AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse.


Interview with Ceo Doug Janzen
http://business.financialpost.com/midas-letter/podcast-aequus-pharmaceuticals-ceo-doug-janzen-on-the-low-cost-of-drug-commercialization-in-canada

James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year?

Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.


James West: Sure. Have you built a pharmaceutical company before, Doug?

Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.